Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan P. Frías, Michael A. Nauck, Joanna Van, et al.
The Lancet (2018) Vol. 392, Iss. 10160, pp. 2180-2193
Closed Access | Times Cited: 658

Showing 1-25 of 658 citing articles:

Glucagon-like peptide 1 (GLP-1)
Timo D. Müller, Brian Finan, Stephen R. Bloom, et al.
Molecular Metabolism (2019) Vol. 30, pp. 72-130
Open Access | Times Cited: 1306
Therapeutic peptides: current applications and future directions
Lei Wang, Nanxi Wang, Wenping Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 1155
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frías, Melanie J. Davies, Julio Rosenstock, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 6, pp. 503-515
Open Access | Times Cited: 1117
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Molecular Metabolism (2020) Vol. 46, pp. 101102-101102
Open Access | Times Cited: 979
Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 688
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock, Carol Wysham, Juan P. Frías, et al.
The Lancet (2021) Vol. 398, Iss. 10295, pp. 143-155
Closed Access | Times Cited: 664
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 9, pp. 599-612
Closed Access | Times Cited: 580
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coşkun, Kyle W. Sloop, Corina Loghin, et al.
Molecular Metabolism (2018) Vol. 18, pp. 3-14
Open Access | Times Cited: 575
Function and mechanisms of enteroendocrine cells and gut hormones in metabolism
Fiona M. Gribble, Frank Reimann
Nature Reviews Endocrinology (2019) Vol. 15, Iss. 4, pp. 226-237
Closed Access | Times Cited: 499
Mechanisms controlling pancreatic islet cell function in insulin secretion
Jonathan E. Campbell, Christopher B. Newgard
Nature Reviews Molecular Cell Biology (2021) Vol. 22, Iss. 2, pp. 142-158
Open Access | Times Cited: 440
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Stefano Del Prato, Steven E. Kahn, Imre Pávó, et al.
The Lancet (2021) Vol. 398, Iss. 10313, pp. 1811-1824
Closed Access | Times Cited: 434
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard Ludvik, Francesco Giorgino, Esteban Jódar, et al.
The Lancet (2021) Vol. 398, Iss. 10300, pp. 583-598
Closed Access | Times Cited: 421
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
Dominik Dahl, Yukiko Onishi, Paul Norwood, et al.
JAMA (2022) Vol. 327, Iss. 6, pp. 534-534
Open Access | Times Cited: 361
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard, Jonathan D. Douros, M Gabe, et al.
JCI Insight (2020) Vol. 5, Iss. 17
Open Access | Times Cited: 301
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J. Samms, Matthew P. Coghlan, Kyle W. Sloop
Trends in Endocrinology and Metabolism (2020) Vol. 31, Iss. 6, pp. 410-421
Open Access | Times Cited: 277
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman, Arun J. Sanyal, Rohit Loomba, et al.
Diabetes Care (2020) Vol. 43, Iss. 6, pp. 1352-1355
Open Access | Times Cited: 267
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Young Jin Tak, Sang Yeoup Lee
Current Obesity Reports (2021) Vol. 10, Iss. 1, pp. 14-30
Open Access | Times Cited: 261
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
Louis J. Aronne, Naveed Sattar, Deborah B. Horn, et al.
JAMA (2023) Vol. 331, Iss. 1, pp. 38-38
Open Access | Times Cited: 261
Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
Maria J. Pereira, Jan W. Eriksson
Drugs (2019) Vol. 79, Iss. 3, pp. 219-230
Open Access | Times Cited: 257
Targeting fibrosis: mechanisms and clinical trials
Manyu Zhao, Liqun Wang, Mengzhu Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 249
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens, Emma K. Biggs, Tamana Darwish, et al.
Cell Metabolism (2019) Vol. 30, Iss. 5, pp. 987-996.e6
Open Access | Times Cited: 243
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Naveed Sattar, Darren K. McGuire, Imre Pávó, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 591-598
Open Access | Times Cited: 239
Therapeutic pipeline in nonalcoholic steatohepatitis
Raj Vuppalanchi, Mazen Noureddin, Naim Alkhouri, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 6, pp. 373-392
Closed Access | Times Cited: 233
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Chengxu Ma, Xiaoni Ma, Conghui Guan, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 227
Advances in therapeutic peptides targeting G protein-coupled receptors
Anthony P. Davenport, Conor C. G. Scully, Chris de Graaf, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 6, pp. 389-413
Open Access | Times Cited: 224
Page 1 - Next Page

Scroll to top